UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~August 121, 2018

DOUGHERTY’S PHARMACY, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 000-27945

Delaware	75-2900905
(State or other jurisdiction	(IRS Employer
of incorporation)	Identification No.)

5924 ROYAL LANE, SUITE 250

DALLAS, TEXAS 75230

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code: 972-250-0945

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

Item 52.0704 ~~Submission~~Triggering ofEvents ~~Matters~~That toAccelerate or Increase a ~~Vote~~Direct ofFinancial ~~Security~~Obligation ~~Holders~~or an Obligation Under an Off Balance Sheet Arrangement

On ~~June~~August 121, 2018, anDougherty’s Pharmacy, ~~annual~~Inc. ~~meeting~~(the “Company”) was obligated to make payment of the ~~stockholders~~outstanding principal of ~~Dougherty’s Pharmacy~~$3,956,192.95 plus ~~Inc~~$18,251.80 in accrued and unpaid interest under a $4,000,000 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (the “~~Company~~Lender”). Failure to make this payment on the August 1, 2018, maturity date was ~~held~~an atevent of default under the ~~Company’s~~Revolver. ~~Corporate~~The ~~Offices~~accrued ~~located~~interest atof $18,251.80 ~~5924~~was ~~Royal~~paid ~~Lane~~on August 2, ~~Suite~~2018. An event of default under the Revolver permits the Lender, among other things, to foreclose ~~250~~on the assets securing the Revolver, ~~Dallas~~which includes certain retail pharmacy assets, ~~Texas~~specifically but not limited to, ~~75230~~inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “~~Annual~~Secured ~~Meeting~~Assets”),. In ~~for~~addition to the ~~stockholders~~failure to ~~vote~~make the payment on the ~~following~~maturity ~~proposals:~~date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver.

~~Proposal~~The 1:Company ~~The~~does ~~election~~not currently have the ability to cure either events of ~~one~~default ~~Class~~under Athe ~~Director~~Revolver. toShould ~~hold~~the Lender elect ~~office~~to ~~until~~foreclose against the ~~2021~~Secured ~~annual~~Assets, ~~meeting~~it ofwould ~~stockholders~~significantly ~~and~~impair ~~until~~the ~~his~~Company's ~~successor~~ability ~~has~~to ~~been~~continue ~~duly~~as ~~elected~~a ~~and~~going ~~qualified~~concern or to even be able to continue its operations. The Company is evaluating all of its options in light of these circumstances.

~~Proposal~~The 2:Company Tois ~~ratify~~evaluating ~~the~~all ~~selection~~of its options in light of ~~Whitley~~these ~~Penn~~circumstances, ~~LLP to~~including, bewithout limitation, refinancing the ~~Company’s~~indebtedness ~~independent~~with ~~registered~~another ~~public~~lender, ~~accounting~~entering into ~~firm~~a ~~for~~settlement or workout arrangement with the ~~fiscal~~Lender, or ~~year~~obtaining ~~ending~~a ~~December~~temporary 31waiver or forbearance from the Lender; provided, ~~2018~~however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and acceptable by the Company.”

The foregoing proposals were the only proposals to be acted upon at the Annual Meeting. For information regarding such proposals, see the Company’s definitive proxy statement filed with the U.S. Securities Exchange Commission by the Company on May 22, 2018, with respect to the Annual Meeting.SIGNATURES

AtPursuant ~~the~~to ~~close of business on April 13, 2018,~~ the ~~record date~~requirements ~~for the Annual Meeting, there were 23,087,164 shares~~ of the ~~Company’s~~Securities ~~common~~Exchange ~~stock~~Act ~~outstanding and entitled to vote at the Annual Meeting (“Common Stock”). As the holders~~ of 201934,~~468,748~~ ~~shares of Common Stock, having a majority of~~ the ~~votes that~~registrant ~~could~~has beduly ~~cast~~caused bythis ~~the~~report ~~holders of all outstanding shares of stock entitled~~ to ~~vote~~be atsigned ~~any~~on ~~meeting~~its ofbehalf ~~the Company’s shareholders, were represented in person or~~ by ~~proxy at~~ the ~~Annual~~undersigned hereunto ~~Meeting,~~duly ~~a quorum was present~~authorized.

~~Each~~Dated: ofAugust ~~the foregoing proposals was adopted and approved by the shareholders at the Annual Meeting. The number of votes cast for or against~~6, ~~as well as abstentions and broker non-votes, if applicable, with respect to each of Proposals 1 and 2 presented at the Annual Meeting are set forth below:~~2018

~~Proposal~~Dougherty’s 1:Pharmacy, ~~The~~Inc. ~~election~~By: of/s/ ~~Troy~~James ~~Phillips~~C. asLeslie aJames ~~Class A~~C. ~~Director~~Leslie toChairman, ~~hold~~Chief ~~office~~Executive ~~until~~Officer, ~~the~~Interim ~~2021~~President, ~~annual~~and ~~meeting~~Interim ofChief ~~stockholders~~Financial ~~and~~Officer ~~until~~(Duly ~~his~~Authorized ~~successor~~Principal ~~has~~Executive ~~been~~Officer ~~duly~~and ~~elected~~Principal ~~and~~Financial ~~qualified.~~Officer)

FOR	AGAINST	ABSTAIN	BROKER NON-VOTE
10,970,417	0	87,283	10,058,896

Proposal 2: To ratify the selection of Whitley Penn LLP to be the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

FOR	AGAINST	ABSTAIN	BROKER NON-VOTE
20,354,697	110,701	3,350	647,848

Item 9.01 Financial Statements and Exhibits

(d) The following exhibit is furnished herewith.

99.1 Press Release Dated June 15, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 15, 2018

Dougherty’s Pharmacy, Inc. By: /s/ James C. Leslie James C. Leslie Chairman, Chief Executive Officer, Interim President, and Interim Chief Financial Officer (Duly Authorized Principal Executive Officer and Principal Financial Officer)

Filing Compare · Dougherty's Pharmacy, Inc.